Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor.

Miao S, Wang SM, Cheng X, Li YF, Zhang QS, Li G, He SQ, Chen XP, Wu P.

Cancer Cell Int. 2017 Dec 11;17:119. doi: 10.1186/s12935-017-0494-7. eCollection 2017.

2.

Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer.

He L, Wu S, Hao Q, Dioum EM, Zhang K, Zhang C, Li W, Zhang W, Zhang Y, Zhou J, Pang Z, Zhao L, Ma X, Li M, Zhang Q.

Oncotarget. 2017 Jul 18;8(47):82352-82365. doi: 10.18632/oncotarget.19354. eCollection 2017 Oct 10.

4.
5.

Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.

Tankiewicz-Kwedlo A, Hermanowicz J, Surażynski A, Rożkiewicz D, Pryczynicz A, Domaniewski T, Pawlak K, Kemona A, Pawlak D.

Mol Cell Biochem. 2016 Oct;421(1-2):1-18. doi: 10.1007/s11010-016-2779-x. Epub 2016 Aug 20.

6.

Reply to T. Hasegawa et al and I. Gross et al.

Leyland-Jones B, Vercammen E, Xiu L.

J Clin Oncol. 2016 Nov 1;34(31):3820-3821. doi: 10.1200/JCO.2016.68.7681. No abstract available.

7.

Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013.

Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, Chao C.

Clin Epidemiol. 2016 Apr 18;8:61-71. doi: 10.2147/CLEP.S89480. eCollection 2016.

8.

Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.

Accordino MK, Wright JD, Vasan S, Neugut AI, Hillyer GC, Hu JC, Hershman DL.

J Clin Oncol. 2016 Aug 20;34(24):2820-6. doi: 10.1200/JCO.2016.66.6313. Epub 2016 May 9.

9.

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.

Mountzios G, Aravantinos G, Alexopoulou Z, Timotheadou E, Matsiakou F, Christodoulou C, Laschos K, Galani E, Koutras A, Bafaloukos D, Linardou H, Pectasides D, Varthalitis I, Papakostas P, Kalofonos HP, Fountzilas G.

Mol Clin Oncol. 2016 Feb;4(2):211-220. Epub 2015 Dec 4.

10.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.

Liedtke C, Thill M, Hanf V, Schuütz F; AGO Breast Committee.

Breast Care (Basel). 2015 Jul;10(3):199-205. doi: 10.1159/000431248. Epub 2015 Jun 18. No abstract available.

11.

Trends in Anemia Management in Hemodialysis Patients with Cancer.

Butler AM, Kshirsagar AV, Olshan AF, Nielsen ME, Wheeler SB, Brookhart MA.

Am J Nephrol. 2015;42(3):206-15. doi: 10.1159/000440771. Epub 2015 Oct 7.

12.

Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.

Rainville N, Jachimowicz E, Wojchowski DM.

Expert Opin Ther Targets. 2016;20(3):287-301. doi: 10.1517/14728222.2016.1090975. Epub 2015 Sep 30. Review.

13.

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J.

Support Care Cancer. 2016 Apr;24(4):1517-25. doi: 10.1007/s00520-015-2929-9. Epub 2015 Sep 14.

14.

Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma.

Meyer FR, Steinborn R, Grausgruber H, Wolfesberger B, Walter I.

Vet J. 2015 Oct;206(1):67-74. doi: 10.1016/j.tvjl.2015.06.003. Epub 2015 Jun 6.

15.

American Society of Nephrology Quiz and Questionnaire 2014: RRT.

Mehrotra R, Perazella MA, Choi MJ.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1100-6. doi: 10.2215/CJN.01490215. Epub 2015 Apr 20.

16.

Oncolytic Poxviruses.

Chan WM, McFadden G.

Annu Rev Virol. 2014 Sep 1;1(1):119-141.

17.

Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck.

Shenouda G, Zhang Q, Ang KK, Machtay M, Parliament MB, Hershock D, Suntharalingam M, Lin A, Rotman M, Nabid A, Hong S, Shehata S, Cmelak AJ, Sultanem K, Le QT.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):907-15. doi: 10.1016/j.ijrobp.2014.12.018. Epub 2015 Feb 7.

18.

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

Izzedine H, Perazella MA.

Nephrol Dial Transplant. 2015 Dec;30(12):1979-88. doi: 10.1093/ndt/gfu387. Epub 2015 Feb 3. Review.

19.

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Hendrick F, Davidoff AJ, Zeidan AM, Gore SD, Baer MR.

Medicare Medicaid Res Rev. 2014 Nov 26;4(4). pii: mmrr2014-004-04-a02. doi: 10.5600/mmrr.004.04.a02. eCollection 2014. Erratum in: Medicare Medicaid Res Rev. 2014;4(4). pii: mmrr2014-004-04-a02_corrigendum.

20.

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.

Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH.

Cancer Sci. 2014 Dec;105(12):1569-75. doi: 10.1111/cas.12544. Epub 2014 Nov 5.

Supplemental Content

Support Center